{"analyses":[{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.68","groupDescription":"This analysis is for Asian participants.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Cox Proportional Hazard","paramValue":"1.11"},{"ciLowerLimit":"0.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.50","groupDescription":"This analysis is for Black or African American participants.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Cox Proportional Hazard","paramValue":"1.06"},{"ciLowerLimit":"0.93","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.37","groupDescription":"This analysis is for White participants.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Cox Proportional Hazard","paramValue":"1.13"},{"ciLowerLimit":"1.03","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.74","groupDescription":"This analysis is for Race of Other participants.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Cox Proportional Hazard","paramValue":"1.34"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.0","upperLimit":"13.0","value":"10"},{"groupId":"OG001","lowerLimit":"9.0","upperLimit":"13.0","value":"10.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.0","upperLimit":"8.0","value":"7.0"},{"groupId":"OG001","lowerLimit":"5.0","upperLimit":"8.0","value":"6.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"79"}],"units":"Participants"}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.0","upperLimit":"8.0","value":"7.0"},{"groupId":"OG001","lowerLimit":"6.0","upperLimit":"9.0","value":"7.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"245"}],"units":"Participants"}],"title":"White"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.0","upperLimit":"8.0","value":"7.0"},{"groupId":"OG001","lowerLimit":"6.0","upperLimit":"11.0","value":"8.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"142"}],"units":"Participants"}],"title":"Other"}],"denoms":[{"counts":[{"groupId":"OG000","value":"515"},{"groupId":"OG001","value":"518"}],"units":"Participants"}],"description":"Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care.","dispersionType":"95% Confidence Interval","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"MEDIAN","populationDescription":"The intent-to-treat (ITT) population includes all participants who were randomized","reportingStatus":"POSTED","timeFrame":"Day 1 through Day 29","title":"Time to Recovery by Race","type":"PRIMARY","unitOfMeasure":"Days"}